Vinblastin Maintenance
Phase 3Small molecule
Vinblastin Maintenance is one of 25 small molecule programs targeting Medulloblastoma. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Medulloblastoma
#DrugCompanyPhaseTrials
1Dacogen
Sun Pharmaceutical Industries, Inc.Approved
Oncovin
Eli LillyPhase 3
Oncovin
Eli LillyPhase 3
Bicnu
MMelissa K Accordino
Approved
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ceenu
AAzurity Pharmaceuticals
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Paraplatin
AAvyxa
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vinblastin Maintenance. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details